ANAPTYSBIO INC. - COMMON STOCK

AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

05 Aug 2022 16:00:00 By Nasdaq GlobeNewswire

AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference

02 Jun 2022 16:05:01 By Nasdaq GlobeNewswire

AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update

04 May 2022 16:15:01 By Nasdaq GlobeNewswire

AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates

27 Apr 2022 16:15:00 By Nasdaq GlobeNewswire

AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer

21 Mar 2022 16:15:00 By Nasdaq GlobeNewswire

AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne

14 Mar 2022 16:20:00 By Nasdaq GlobeNewswire

AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update

07 Mar 2022 08:50:00 By Nasdaq GlobeNewswire

AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference

05 Jan 2022 16:05:00 By Nasdaq GlobeNewswire

AnaptysBio Announces Appointment of Daniel Faga to Board of Directors

29 Nov 2021 16:05:50 By Nasdaq GlobeNewswire

AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference

15 Nov 2021 19:24:01 By Nasdaq GlobeNewswire

AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data

15 Nov 2021 09:00:01 By Nasdaq GlobeNewswire

AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates

04 Nov 2021 16:05:03 By Nasdaq GlobeNewswire

AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard

25 Oct 2021 16:37:00 By Nasdaq GlobeNewswire

AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis

02 Oct 2021 12:00:00 By Nasdaq GlobeNewswire

AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

09 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

17 Aug 2021 16:32:07 By Nasdaq GlobeNewswire

AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

27 May 2021 16:15:00 By Nasdaq GlobeNewswire

AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

04 May 2021 16:05:01 By Nasdaq GlobeNewswire

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

23 Apr 2021 10:31:07 By Nasdaq GlobeNewswire

FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer

22 Apr 2021 16:12:22 By Nasdaq GlobeNewswire